GSK Files Patent Infringement Suit Against Moderna
GSK Files Patent Infringement Suit Against Moderna

GSK Files Patent Infringement Suit Against Moderna

News summary

GlaxoSmithKline (GSK) has filed a lawsuit against Moderna in Delaware federal court, accusing the biotech firm of infringing on its patents related to messenger RNA (mRNA) technology used in the COVID-19 vaccine Spikevax. GSK claims that Moderna's lipid nanoparticles for mRNA delivery violate several of its patents, which were developed over a decade ago by a team led by vaccinologist Christian Mandl. The litigation seeks unspecified monetary damages, and GSK is open to licensing the patents under reasonable terms. This lawsuit adds to the ongoing patent disputes in the pharmaceutical industry, including a previous case GSK brought against Pfizer and BioNTech. Moderna has expressed its intention to defend itself vigorously against the claims. Both companies face declining vaccine sales, with Moderna reporting $6.7 billion in revenue from Spikevax last year.

Story Coverage
Bias Distribution
50% Center
Information Sources
09bc43f5-e425-4ffd-980d-14d8f4a28792a3544a73-dab3-486d-ae75-bd4d15f01f55
Left 50%
Center 50%
Coverage Details
Total News Sources
3
Left
1
Center
1
Right
0
Unrated
1
Last Updated
35 days ago
Bias Distribution
50% Center
Related News
Daily Index

Negative

20Serious

Neutral

Optimistic

Positive

Ask VT AI
Story Coverage

Related Topics

Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Related News
Recommended News